Clinical Trial Update: Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 trial evaluating zoledronic acid to reduce subsequent osteoporotic fractures after a hip fracture.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hip Fracture
• Osteoporosis

Drugs mentioned

• RECLAST (ZOLEDRONIC ACID)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Osteoporosis, Hip Fracture | Phase 3 | Status: COMPLETED